[(68)Ga-labeled peptides for clinical trials - production according to the German Drug Act: the Göttingen experience].

MLA

Meller, Birgit, et al. “[(68)Ga-Labeled Peptides for Clinical Trials - Production According to the German Drug Act: The Göttingen Experience].” Nuklearmedizin. Nuclear Medicine, vol. 51, no. 2, 2012, pp. 55–64. EBSCOhost, https://doi.org/10.3413/nukmed-0435-11-10.

APA

Meller, B., Angerstein, C., Liersch, T., Ghadimi, M., Sahlmann, C.-O., & Meller, J. (2012). [(68)Ga-labeled peptides for clinical trials - production according to the German Drug Act: the Göttingen experience]. Nuklearmedizin. Nuclear Medicine, 51(2), 55–64. https://doi.org/10.3413/nukmed-0435-11-10

Chicago

Meller, Birgit, C Angerstein, T Liersch, M Ghadimi, C-O Sahlmann, and J Meller. 2012. “[(68)Ga-Labeled Peptides for Clinical Trials - Production According to the German Drug Act: The Göttingen Experience].” Nuklearmedizin. Nuclear Medicine 51 (2): 55–64. doi:10.3413/nukmed-0435-11-10.